Peri-operative immunotherapy with OK-432.
Pre- and postoperative intradermal administration of OK-432 enhanced the SU-PS skin reaction in patients with gastric cancer, but failed to prevent a fall in the NK activity induced by the operation. The change in NK activity was not associated with a change in the proportion of Leu 7-positive cells, but was related to Leu 11a-positive cells. Intradermal injection of OK-432 increased the proportion of Leu 7-positive cells in the patients in whom they accounted for less than 20% of lymphocyte population. The case was the same with Leu 11a-positive cells. Intravenous injection of OK-432 tended to increase suppressor-inducer T cells (CD4+2HA+ cells), B cells and Leu 7-positive cells. Particularly, the proportions of OK-M1-positive cells and MHC class II antigen-positive cells increased in all patients. Immunotherapy with OK-432 given intravenously at a dose of 0.1 KE appeared to be safe because no side effects were essentially observed.
Yokota
M
M
First Department of Surgery, Nagasaki University, Japan.
Tagawa
Y
Y
Okada
D
D
Yasutake
T
T
Mine
Y
Y
Ishikawa
H
H
Miyashita
K
K
Tomita
M
M
Tabuchi
S
S
D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D006801:Humans; D007167:Immunotherapy; D007275:Injections, Intravenous; D016131:Lymphocyte Subsets / Q000187:drug effects; D010844:Picibanil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011182:Postoperative Care; D011300:Preoperative Care; D013274:Stomach Neoplasms / Q000601:surgery / Q000628:therapy
D010844:Picibanil